A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care
Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
Approximately 18-45 patients with Hepatocellular Carcinoma (HCC) will be treated with DENSPM
at approximately 5 centers in the United States. First, we will be trying to determine the
highest dose that can be given safely and is well tolerated (this is called the maximally
tolerated dose, or the MTD, for short). Once that is established, we will enroll additional
patients to learn more about potential side effects and to see whether DENSPM can slow the
growth of HCC tumors. We also want to learn about the safety of DENSPM. Many medications used
to treat cancer cause side effects (discomforts or illness). In this study, we want to
understand what side effects occur in patients with HCC who are treated with DENSPM.Study was
terminated after initial assessment of insufficient data to support clinical benefit in this
population.